Rigel Pharmaceuticals Inc Cash Flow Conversion Efficiency
Rigel Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Rigel Pharmaceuticals Inc (RIGL) has a cash flow conversion efficiency ratio of 0.072x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($30.65 Million) by net assets ($425.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Rigel Pharmaceuticals Inc (1999–2025)
Cash flow conversion efficiency of Rigel Pharmaceuticals Inc from 1999 to 2025. This chart illustrates how Rigel Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View RIGL share price today for real-time trading data and today's change.
Rigel Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Rigel Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Rigel Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rigel Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see RIGL stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Changsha DIALINE New Material Sci & Tech Co Ltd
SHE:300700
|
-0.041x |
|
Fengfan Power
SHG:601700
|
0.096x |
|
Delong Composite Energy Group Co Ltd
SHE:000593
|
0.009x |
|
Cimsa Cimento Sanayi ve Ticaret AS
IS:CIMSA
|
0.029x |
|
Minerals 260 Ltd
AU:MI6
|
-0.038x |
|
Jiangsu Libert Inc
SHG:605167
|
0.005x |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
0.034x |
|
Jiajiayue Group Co Ltd
SHG:603708
|
0.242x |
Annual Cash Flow Conversion Efficiency for Rigel Pharmaceuticals Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Rigel Pharmaceuticals Inc from 1999 to 2025. Review Rigel Pharmaceuticals Inc (RIGL) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $391.48 Million | $75.66 Million | 0.193x | -97.98% |
| 2024-12-31 | $3.29 Million | $31.47 Million | 9.571x | +4673.90% |
| 2023-12-31 | $-28.64 Million | $-5.74 Million | 0.200x | -96.30% |
| 2022-12-31 | $-13.62 Million | $-73.76 Million | 5.417x | +2699.19% |
| 2021-12-31 | $30.37 Million | $5.88 Million | 0.194x | +112.62% |
| 2020-12-31 | $34.03 Million | $-52.19 Million | -1.534x | -98.83% |
| 2019-12-31 | $53.81 Million | $-41.51 Million | -0.771x | -44.07% |
| 2018-12-31 | $109.88 Million | $-58.83 Million | -0.535x | +30.52% |
| 2017-12-31 | $100.65 Million | $-77.56 Million | -0.771x | +44.12% |
| 2016-12-31 | $55.03 Million | $-75.89 Million | -1.379x | -438.27% |
| 2015-12-31 | $91.38 Million | $-23.41 Million | -0.256x | +52.89% |
| 2014-12-31 | $128.25 Million | $-69.75 Million | -0.544x | -31.61% |
| 2013-12-31 | $208.25 Million | $-86.06 Million | -0.413x | -40.24% |
| 2012-12-31 | $289.10 Million | $-85.19 Million | -0.295x | -0.31% |
| 2011-12-31 | $236.15 Million | $-69.38 Million | -0.294x | -204.41% |
| 2010-12-31 | $166.13 Million | $46.74 Million | 0.281x | +130.08% |
| 2009-12-31 | $109.87 Million | $-102.78 Million | -0.935x | +5.87% |
| 2008-12-31 | $104.17 Million | $-103.52 Million | -0.994x | -56.44% |
| 2007-12-31 | $82.18 Million | $-52.21 Million | -0.635x | -54.63% |
| 2006-12-31 | $87.23 Million | $-35.84 Million | -0.411x | -26.84% |
| 2005-12-31 | $108.59 Million | $-35.17 Million | -0.324x | +55.60% |
| 2004-12-31 | $52.30 Million | $-38.15 Million | -0.729x | +10.11% |
| 2003-12-31 | $39.97 Million | $-32.44 Million | -0.812x | +40.20% |
| 2002-12-31 | $25.44 Million | $-34.53 Million | -1.357x | -145.78% |
| 2001-12-31 | $28.94 Million | $-15.98 Million | -0.552x | -133.54% |
| 2000-12-31 | $49.01 Million | $-11.59 Million | -0.236x | +97.72% |
| 1999-12-31 | $756.00K | $-7.83 Million | -10.358x | -- |
About Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relap… Read more